Neurogene to Participate in Upcoming Investor Conferences
February 29 2024 - 7:30AM
Business Wire
Neurogene Inc. (NASDAQ: NGNE) (“Neurogene” or “the Company”), a
clinical-stage company founded to bring life-changing genetic
medicines to patients and families affected by rare neurological
diseases, today announced that Company management will participate
in the following investor conferences:
TD Cowen 44th Annual Health Care Conference Format:
Management will participate in a CNS Corporate Panel and investor
meetings Date: Tuesday, March 5 at 10:30 a.m. ET Leerink Partners
Global Biopharma Conference Format: Management will participate in
investor meetings Date: Monday, March 11 Stifel 2024 Virtual CNS
Days Format: Management will participate in a fireside chat
Date: Wednesday, March 20 at 9:30 a.m. ET
Live webcasts of the panel and fireside chat can be accessed
from the Investor Relations section of Neurogene’s website under
events, where a replay of the events will also be available for a
limited time.
About Neurogene
The mission of Neurogene is to treat devastating neurological
diseases to improve the lives of patients and families impacted by
these rare diseases. Neurogene is developing novel approaches and
treatments to address the limitations of conventional gene therapy
in central nervous system disorders. This includes selecting a
delivery approach to maximize distribution to target tissues and by
designing products to maximize potency and purity for an optimized
efficacy and safety profile. The Company’s novel and proprietary
EXACT transgene regulation platform technology allows for the
delivery of therapeutic levels while limiting transgene toxicity
associated with conventional gene therapy. Neurogene has
constructed a state-of-the-art gene therapy manufacturing facility
in Houston, Texas. CGMP production of NGN-401 was conducted in this
facility and will support pivotal clinical development activities.
For more information, visit www.neurogene.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229815231/en/
Neurogene Contacts: Investor Relations: Melissa Forst
Argot Partners Neurogene@argotpartners.com Media: David Rosen Argot
Partners david.rosen@argotpartners.com
Neurogene (NASDAQ:NGNE)
Historical Stock Chart
From Nov 2024 to Dec 2024
Neurogene (NASDAQ:NGNE)
Historical Stock Chart
From Dec 2023 to Dec 2024